Greykasell Wealth Strategies’s AstraZeneca AZN Stock Holding History

Greykasell Wealth Strategies’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$136K	Hold	690	–	–	0.05%	168
2025 Q4	$127K	Hold	690	–	–	0.05%	170
2025 Q3	$106K	Hold	690	–	–	0.04%	172
2025 Q2	$96.4K	Hold	690	–	–	0.05%	163
2025 Q1	$101K	Buy	+690	New	+$99.8K	0.05%	156

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Greykasell Wealth Strategies's AZN Position: Q1 2026 in Review

Greykasell Wealth Strategies held its AstraZeneca (AZN) position steady in Q1 2026 at 690 shares worth $136K. The position accounts for 0.05% of the portfolio, ranked #168.

Greykasell Wealth Strategies first reported a position in AZN in Q1 2025 and has held it in 5 quarters since. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Greykasell Wealth Strategies held 690 shares of AstraZeneca worth $136K as of Q1 2026.
Greykasell Wealth Strategies left its AstraZeneca share count unchanged in Q1 2026.
AstraZeneca made up 0.05% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #168 holding.
Greykasell Wealth Strategies first reported a position in AstraZeneca in Q1 2025 and has held it in 5 quarters since.
1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.